Feed/Investors/Columbia IMC

Columbia IMC

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on one round in the feed.

Since 2025-11-03

ROUNDS

joined, none as lead

ROUNDS JOINED · USD

$141M

across 1 round

LATEST ROUND

Series B · $141M · 2025-11-03

CO-INVESTORS

named beside it

Rounds

[ 1 ]

The rounds this investor is named on, who it invests beside, and where it shows up.

Company	Round	Amount	Announced	Role
AAVantgarde AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need	Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$141M	2025-11-03	[ PART ]